MDM2 and cancer: Several narrative reviews acknowledge the potential of molecular-radiomics integration in BSTTs, referencing candidate markers such as IDH mutations, MDM2 amplification, and miRNA expression; but these are typically discussed hypothetically or in reference to parallel findings in other cancers (1, 2, 17).